OAC
TVRD

OMERS Administration Corp’s Tvardi Therapeutics TVRD Stock Holding History

OMERS Administration Corp’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-719
Closed -$476K – 528
2017
Q1 		$476K Buy
+719
New +$384K 0.01% 267

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OMERS Administration Corp's TVRD Position: Q2 2017 in Review

OMERS Administration Corp sold out of Tvardi Therapeutics (TVRD) in Q2 2017, closing a stake of 719 shares — an estimated $476K sold.

OMERS Administration Corp first reported a position in TVRD in Q1 2017 and held it in 1 quarter. The position peaked at $476K in Q1 2017. 127 funds tracked by Wall St. Rank hold TVRD as of Q2 2017.

  • OMERS Administration Corp reported no remaining Tvardi Therapeutics position as of Q2 2017 after selling out during the quarter.
  • OMERS Administration Corp sold 719 Tvardi Therapeutics shares in Q2 2017, an estimated $476K.
  • OMERS Administration Corp first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 1 quarter.
  • OMERS Administration Corp's Tvardi Therapeutics position peaked at $476K in Q1 2017.
  • 127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2017.

Based on OMERS Administration Corp's 13F filing for Q2 2017, filed 8 Aug 2017.